Psychedelics venture studio Nucleus has raised USD$135,000 from investors through its Wefunder campaign.
Alternative asset investor platform alts.co has invested $25,000 in the company through its ALTS 1 Fund after featuring the company’s raise in one of its deep dive analyses.
Nucleus has stated it is now well on its way to generating the $500,000 fundraising goal that it has set, and that it continues to build momentum with its multi-brand infrastructure, which is supported by its evolving technologies and growing audiences.
Alts CEO, Stefan Von Imhof, commented: “Nucleus is a venture studio, meaning they’re taking several swings at the space rather than putting all their eggs in one basket.
”Their various ventures have so far all been ‘picks and shovels’ plays — marketing, data, and directories. And stuff that will rise alongside the psychedelic tide is a much safer bet than picking one specific drug or therapy to bet on.
“Will Nucleus be a homerun in three years? Perhaps. Will it double or triple? We think so. And that’s why we chose to invest $25k in their WeFunder campaign.”
CEO of Nucleus, Logan Lenz, added: “We’re so appreciative of the team at Alts and their unbiased perspective on the alternative investment landscape.
“It’s validating to see such savvy investors like them align with the Nucleus vision and recognise the massive growth opportunity we have in front of us. It’s investors like them and the ALTS 1 Fund that makes us proud that we’re crowdfunding and allowing anybody with $200 and a Wefunder account to invest and share in Nucleus’ success.”
Last week, the Nucleus company Psyrise announced the launch of the first end-to-end marketing platform for ketamine clinics, retreats, and psychedelic-assisted therapists.
